The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HLS Therapeutics's Revenue for the
three
months ended in Mar. 2026 was C$17.65 Mil. HLS Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was C$9.83 Mil.
Hence, HLS Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.80.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
HLS Therapeutics Receivables Turnover Related Terms
HLS Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:HLS vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a Receivables Turnover of 1.80 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HLS Therapeutics and its competitors. According to the industry distribution chart, HLS Therapeutics ranks #244 out of 947 companies in the Drug Manufacturers industry, placing it in the top 25.8%.
Is HLS Therapeutics' Receivables Turnover too high?
HLS Therapeutics' current Receivables Turnover is 1.80. The Drug Manufacturers industry median Receivables Turnover is 5.07. HLS Therapeutics' value of 1.80 is 64.5% below this industry median. Based on the distribution chart, HLS Therapeutics ranks #244 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, HLS Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #244 out of 947 companies for Receivables Turnover. This puts HLS Therapeutics in the upper half of its industry. The industry median Receivables Turnover is 5.07. HLS Therapeutics' value of 1.80 is 64.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current Receivables Turnover of 1.80 is 64.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current Receivables Turnover is 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.50, compared to a current price of C$4.29 — trading 4.7% below its estimated fair value. The current Receivables Turnover is 1.80 and 64.5% below the Drug Manufacturers industry median of 5.07. HLS Therapeutics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Receivables Turnover is 1.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.29 is trading 4.7% below its estimated GF Value™ of C$4.50.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Receivables Turnover: 1.80
GF Value™: C$4.50 vs. price of C$4.29 (4.7% below fair value)
Industry Position: 64.5% below the Drug Manufacturers median (#244 of 947)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
67GF Score
Get the complete analysis for TSX:HLS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
